|
1) Farquhar MG, Palade GE. Behavior of colloidal particles in the glomerulus. Anat Rec. 1959; 133: 378-89
|
|
|
|
|
2) Farquhar MG, Abrahamson DR. Milestones in nephrology: Glomerular permeability. J Am Soc Nephrol. 1999; 10: 2645-62
|
|
|
|
|
3) Kanwar YS, Danesh FR, Chugh SS. Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective. Am J Pathol. 2007; 171: 9-13
|
|
|
|
|
4) Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell. 1998; 1: 575-82
|
|
|
|
|
|
5) Comper WD, Glasgow EF. Charge selectivity in kidney ultrafiltration. Kidney Int. 1995; 47: 1242-51
|
|
|
|
|
|
6) Schaeffer RC, Gratrix ML, Mucha DR, et al. The rat glomerular filtration barrier does not show negative charge selectivity. Microcirculation. 2002; 9: 329-42
|
|
|
|
|
|
7) Zenker M, Aigner T, Wendler O, et al. Human laminin beta-2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Molec Genet. 2004; 13: 2625-32
|
|
|
|
|
|
8) Jarad G, Cunningham J, Shaw AS, et al. Proteinuria precedes podocyte abnormalities in Lamb2 -/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest. 2006; 116: 2272-9
|
|
|
|
|
|
9) Morita H, Yoshimura A, Kimata K. The role of heparan sulfate in the glomerular basement membrane. Kidney Int. 2008; 73: 247-8
|
|
|
|
|
|
10) Xiong S, Zhang L, He QY. Fractionation of proteins by heparin chromatography. Methods Mol Biol. 2008; 424: 213-21
|
|
|
|
|
|
11) Utriainen A, Sormunen R, Kettunen M, et al. Structurally altered basement membranes and hydrocephalus in type XVIII collagen deficient mouse line. Hum Mol Genet. 2004; 13: 2089-99
|
|
|
|
|
|
12) Groffen AJ, Ruegg MA, Dijkman H, et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem. 1998; 46: 19-27
|
|
|
|
|
|
13) Morita H, Yoshimura A, Inui K, et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol. 2005; 16: 1703-10
|
|
|
|
|
|
14) Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol. 2008; 4: 24-37
|
|
|
|
|
|
15) van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006; 70: 2100 -8
|
|
|
|
|
|
16) Kramer A, van den Hoven M, Rops A, et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol. 2006; 17: 2513 -20
|
|
|
|
|
|
17) Levidiotis V, Freeman C, Tikellis C, et al. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol. 2004; 15: 68-78
|
|
|
|
|
|
18) Levidiotis V, Kanellis J, Ierino FL, et al. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int. 2001; 60: 1287-96
|
|
|
|
|
|
19) Levidiotis V, Freeman C, Tikellis C, et al. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton). 2005; 10: 167-73
|
|
|
|
|
|
20) Rops AL, van den Hoven M, Bakker MA, et al. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis. Nephrol Dial Transplant. 2007; 22: 1891-902
|
|
|
|
|
|
21) van den Hoven MJ, Wijnhoven TJ, Li JP, et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int. 2008; 73: 278-87
|
|
|
|
|
|
22) Wijnhoven TJ, Lensen JF, Wismans RG, et al. In vivo degradation of heparan sulfate in the glomerular basement membrane does not result in proteinuria. J Am Soc Nephrol. 2007; 18: 823 -32
|
|
|
|
|
|
23) Harvey SJ, Jarad G, Cunningham J, et al. Moeller MJ, Holzman LB, Burqess RW, Minor JH. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol. 2007; 171: 139-52
|
|
|
|
|
|
24) Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, et al. Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int. 2008; 74: 289-99
|
|
|
|
|
|
25) Roberts IS, Gleadle JM. Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation. J Am Soc Nephrol. 2008; 19: 450-3
|
|
|
|
|
|
26) Singh A, Satchell SC, Neal CR, et al. Endothelial cell glycocalyx in the glomerular barrier. J Am Soc Nephrol. 2007; 18: 2885-93
|
|
|
|
|
|
27) Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol. 2006: 290: F111-6
|
|
|
|
|
|
28) Ballermann B, Stan R. Resolved: Capillary endothelium is a major contributor to the glomerular filtration barrier. J Am Soc Nephrol. 2007; 18: 2432-8
|
|
|
|
|
|
29) Bolton GR, Deen WM, Daniels BS. Assessment of the charge selectivity of glomerular basement membrane using Ficoll sulfate. Am J Physiol Renal Physiol. 1998; 274: F889-96
|
|
|
|
|
|
30) Galeano B, Klootwijk R, Manoli I, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest. 2007; 117: 1585-94
|
|
|
|
|
|
31) Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes. 2005; 54: 2172-8
|
|
|
|
|
|
32) Myrup B, Hansen PM, Jensen T, et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet. 1995; 345: 421-2
|
|
|
|
|
|
33) Tamsma JT, van der Woude FJ, Lemkes HHPJ. Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant. 1996; 11: 182-5
|
|
|
|
|
|
34) Dedov I, Shestakova M, Vorontzov A, et al. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997; 12: 2295- 300
|
|
|
|
|
|
35) Szelanowska M, Poplawska A, Topolska J, et al. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type 1 diabetic patients. Curr Med Res Opin. 1997; 13: 539-45
|
|
|
|
|
|
36) Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial. J Am Soc Nephrol. 2002; 13: 1615-25
|
|
|
|
|
|
37) Lewis EJ, Lewis JB, Hunsicker LG, for the Collaborative Study Group. Interim analysis of a pilot trial of sulodexide in type 2 diabetic nephropathy with microalbuminuria (Abstract). J Am Soc Nephrol. 2005; 16: 58A
|
|
|
|
|